AKIMYO RUSSELL: Open Payments
NPI 1295928570 · ALEXANDRIA, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$889 in 32 payments from 15 companies in 2025. Trend: 2023 $493 · 2024 $439 · 2025 $889
Food & beverage: $870Consulting: $20
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 5 | $192 |
| AstraZeneca Pharmaceuticals LP | 8 | $175 |
| GENZYME CORPORATION | 3 | $94 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $83 |
| Amgen Inc. | 2 | $59 |
| GlaxoSmithKline, LLC. | 2 | $48 |
| Regeneron Healthcare Solutions, Inc. | 1 | $37 |
| Genentech USA, Inc. | 1 | $34 |
| Grifols USA, LLC | 1 | $32 |
| CSL Behring | 1 | $27 |
Products named: TEZSPIRE, DUPIXENT, CIBINQO, OCTAGAM IMMUNE GLOBULIN (HUMAN), FASENRA, CUVITRU, Xolair, Prolastin-C Liquid.
Industry payments across VA — which companies pay providers there.
